Print Page   |   Sign In   |   Join ISSX
ISSX Workshop on LC-MS Proteomics

Towards Reaching a Consensus on Using Quantitative LC-MS/MS
Proteomics in Translational DMPK/PD Research

 

September 27 & 28, 2018

Takeda Pharmaceuticals USA, Inc. Auditorium

Cambridge, Massachusetts, USA

 


 

About the Workshop

For in vitro-in vivo extrapolation (IVIVE) of drug absorption, distribution, metabolism, excretion (ADME), pharmacodynamics (PD) and drug-drug interactions (DDI), quantitative systems pharmacology (QSP) models, including physiologically-based pharmacokinetic (PBPK) models, rely heavily on physiological parameters, such as the abundance of proteins in tissues important in these processes. A significant obstacle in quantification of the abundance of ADME and PD proteins is that conventional methods (e.g. Western blotting) cannot be used when purified standards of these proteins (e.g. transporters, receptors) are not available.  Moreover, these conventional methods lack specificity, are low throughput and cumbersome.  The advent of quantitative proteomics (QPr), based on LC-MS/MS, has overcome many of these disadvantages. Though this approach is increasingly being adopted by many laboratories, differences in its implementation have led to large differences in the reported abundance of ADME proteins. Therefore, the goals of this workshop are three-fold:

  1. To have key opinion leaders with extensive experience with QPr share their viewpoints and debate the best practices in its implementation

  2. To publish a consensus “white paper” on these best practices

  3. To educate scientists interested in implementing QPr in their laboratories on the choices, advantages, disadvantages and pitfalls of QPr. 

Who Should Attend

Scientist who want to learn about and contribute to:

  • A debate on best practices in quantification of abundance of proteins using QPr and IVIVE of PK, PD and DDI during drug development

  • A debate on advantages, disadvantages and pitfalls of QPr

  • How to implement QPr in a laboratory, the cost-benefit ratio of the method, and the utility of the method in drug development

  • A debate on best practices in using QPr data for IVIVE of PK, PD and DDI during drug development

  • A consensus “white paper” on best practices in QPr and in using QPr data for IVIVE of PK, PD and DDI

  • A network of scientists working in QPr

What do I Gain by Attending this Workshop?

  • Get introduced to the latest range of LC-MS proteomics techniques relevant to drug development activities

  • Get informed about similarities and discrepancies between different protocols of sample preparation and tools for quantitative LC-MS proteomics

  • Learn about applications of LC-MS proteomics within PBPK and IVIVE and significance of variations introduced by different techniques

  • Inform yourself about cost-benefit ratios of various methodologies and how they fit your needs

  • Enhance your knowledge required for making decisions on selecting the right method for your intended purpose

  • Get introduced to the key players in the space of quantitative LC-MS proteomics for conduct of IVIVE for drug metabolising enzymes and transporters
  • Gain insights into on-going debates and hot topics that engage the key opinion leaders in the field

  • Hear the consensus on unsettled issues well before they get published and appear in the literature

  • Create a Network with those working in the space or intending to enter into the space of quantitative LC-MS proteomics in drug development

Register Today!

Association Management Software Powered by YourMembership  ::  Legal